New PMPRB report shows significant consistency in public drug plan coverage across Canada for drugs subject to “Common Drug Review” process

The Patented Medicine Prices Review Board (PMPRB) released today the third and final part in the Alignment Among Public Formularies in Canada series, which explores the current gaps and overlaps in Canadian public drug plan formularies Отсюда - | Перевод - Яндекс.

Comments are closed.